Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
ASNC rejects new chest pain guideline it helped create
November 2, 2021
“We believe that the document fails to provide unbiased guidance to health care professionals on the optimal evaluation of patients with chest pain.”
New reports help nail down myocarditis risk with COVID-19 vaccine
October 11, 2021
Myocarditis linked to the two mRNA SARS-CoV-2 vaccines is rare, usually mild and self-limited, and a lot less likely than the usually more severe cases seen in COVID-19.
Is AFib a stroke cause or innocent bystander? The debate continues
October 5, 2021
Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.
DOACs best aspirin after ventricular ablation: STROKE-VT
August 2, 2021
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.
ESC heart failure guideline to integrate bounty of new meds
July 29, 2021
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.
Are left atrial thrombi that defy preprocedure anticoagulation predictable?
June 11, 2021
Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-control procedures.
New light cast on type 2 MI aims to sharpen diagnosis, therapy
February 23, 2021
A large survey of type 2 MI, triggered when myocardial oxygen demand outstrips supply, points to confusion hindering its diagnosis and treatment and reveals the rarity of revascularization.
FDA expands sacubitril/valsartan indication to embrace some HFpEF
February 17, 2021
The newly approved labeling for sacubitril/valsartan (Entresto) is simply for “chronic heart failure” but almost teasingly adds, “the benefits are most clearly evident” at below-normal LVEF.
Myocarditis by CMR may be rare after COVID-19 in elite athletes
January 27, 2021
Some supposed ‘myocarditis’ detected by MRI after COVID-19 in university varsity competitors might be normal heart muscle – normal for athletes, that is, propose researchers.